CDI cases | Non-RT027 | RT027 | p valuesa | ||
---|---|---|---|---|---|
Median age | 73.08 (range 54–87) | 71.63 | 74.13 | ||
Sex | female | 16 | 6 | 10 | 0.41 |
male | 10 | 5 | 5 | 0.41 | |
Hospitalization on septic/non-septic ward | septic ward | 21 | 7d | 14 | 0.04 |
all other wards | 5 | 4 b,c | 1 | ||
Primary diagnosis | periprosthetic infection | 19 | 8 | 11 | 0.81 |
soft tissue / wound infection | 4 | 1 | 3 | ||
spondylitis | 2 | 2 | 0 | ||
osteomyelitis | 1 | 0 | 1 | ||
Co-morbidities | renal insufficiency | 12 | 4 | 8 | 0.41 |
diabetes | 11 | 5 | 6 | ||
pneumonia | 1 | 0 | 1 | ||
neoplasm | 2 | 1 | 1 | ||
hepatic disease | 2 | 1 | 1 | ||
Antimicrobial therapy | aminopenicillins | 4 | 1 | 3 | 0.72 |
ureidopenicillins | 6 | 2 | 4 | 0.42 | |
fluoroquinolones | 9 | 3 | 6 | 0.27 | |
cephalosporins | 13 | 5 | 8 | 0.24 | |
clindamycin | 7 | 3 | 4 | 0.81 | |
rifampicin | 13 | 6 | 7 | 0.69 | |
Gastric acid suppressors | proton pump inhibitors/H2 blockers | 25 | 11 | 14 | |
Severity factors | creatinine (>1.5x103g/L) | 7 | 3 | 4 | 0.99 |
leukocytosis (>1.5x109/L) | 10 | 4 | 6 | 0.93 | |
Antimicrobial CDI treatment | |||||
First episode | metronidazole po. | 18 | 8 | 10 | |
vancomycin po. | 1 | 0 | 1 | ||
metronidazole iv. vancomycin po. | 2 | unknown | unknown | ||
fidaxomicin po. | 4 | 1 | 3 | ||
colectomy | 1 | 0 | 1 | ||
no treatment | 1 | 0 | 1 | ||
Recurrence | vancomycin po. | 5 | 2 | 3 | |
metronidazole iv. + vancomycin po. | 1 | 0 | 1 | ||
fidaxomicin po. | 3 | 1 | 2 | ||
fecal biota transplantation | 1 | 0 | 1 | ||
Clinical outcome | cure | 15 | 9 | 6 | 0.21 |
recurrence | 10 | 3 | 7 | 0.37 | |
death within 6 months | 4 | 0 | 4 | 0.13 | |
death CDI attributed | 1 | 0 | 1 | ||
death CDI contributed | 3 | 0 | 3 |